# US 2015/0087581 A1 · Immunosuppression Modulating Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0087581 A1
- Document ID: US20150087581A1
- Status: Published application
- Kind: A1
- Application number: 14/563,568
- Filed: 2014-12-08
- Published: 2015-03-26
- Earliest claimed: 2010-06-25
- Assignees: Aurigene Discovery Technologies Limited
- Inventors: Pottayil Govindan Nair Sasikumar; Muralidhara Ramachandra; Suresh Kumar Vadlamani; Koteswara Rao Vemula; Leena Khare Satyam; Krishnaprasad Subbarao; K. Rajeev Shrimali; Sreenivas Kandepu
- Web page: https://patentgrep.com/patent/US20150087581A1

## CPC

- C07K 14/001: {by chemical synthesis}
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 9/00: Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides immunosuppression compounds to inhibit the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides an application of the compositions containing the peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease.

## Claims

### Claim 1

A compound of formula (I)
or pharmaceutically acceptable salt thereof;
wherein;
A is an amino acid sequence of from three amino acids to the full length of a peptide sequence of mammalian PD1 ectodomain fragments selected from FG loop, BC loop, C-C′ loop, C strand, C′ strand to C′-C″ loop, or is Glu-Asp;
B is an amino acid sequence of from three amino acids to the full length of a peptide sequence of mammalian PD1 ectodomain fragments selected from BC loop, FG loop, C C′ loop to C′ strand, C strand, D strand, C′ strand to C′-C″ loop, or is Glu-Asp, or is absent;
with the proviso that if A is the amino acid sequence SNTSESF and X is lysine then B cannot be the amino acid sequence SNTSESF;
Z is
(i) from one to four peptide sequences arranged in any order each being of from three amino acids up to the full length of a mammalian PD1 ectodomain fragment selected from BC loop, D strand, FG loop, G strand, C strand, F strand, C′ strand, C″ strand, C″-D loop, C′ strand to C′-C″ loop, C′ strand to C″ strand or D strand to DE loop;
(ii) G-L-Z′
G is an amino acid sequence of from three amino acids to the full length of a peptide sequence of mammalian PD1 ectodomain fragments from D-strand or is absent;
L is selected from —CO(CH2)n—NH—, or PEG 2-20 KD;
‘n’ is an integer selected from 2 to 10, both inclusive; and
Z′ is one to three peptide sequences arranged in any order each being of from three amino acids up to the full length of a mammalian PD1 ectodomain fragment selected from FG loop and G-strand; or
(iii) from one to four peptide sequences arranged in any order each being of from three amino acids up to the full length of a mammalian PD1 ectodomain fragment selected from D-strand, FG loop and G strand, wherein two or more amino acids of the peptide sequence combine together to form a lactam bond between any of the two fragments or within the fragment;
D is up to two peptide sequences arranged in any order each being of from three amino acids up to the full length of a mammalian PD1 ectodomain fragment selected from BC loop, FG loop, C C′ loop to C′ strand or is absent;
E is up to four peptide sequences arranged in any order each being of from three amino acids up to the full length of a mammalian PD1 ectodomain fragment selected from BC loop, D strand, FG loop, C C′ loop to C′ strand, G strand, FG loop to G strand or is absent;
X and X′ are independently selected from lysine, ornithine, diaminopropionic acid, diaminobutyric acid or olefinic amino acid of formula
which is optionally linked with an additional lysine; or
X and X′ combine together forming a ring with olefinic amino acid which is optionally linked with an additional lysine; or
X′ is absent;
‘m’ is an integer selected from 1 to 6, both inclusive;
R1 is selected from group consisting of C2-C20 acyl, PEG 2-20 KD moiety; or absent, R2 and R3 are independently selected from group consisting of C2-C20 acyl, PEG 2-20 KD, absent or Ra-L′;
Ra is selected from biotin or maleimido propionic acid;
L′ is selected from linkers —CO(CH2)n—NH—, —CO(CH2—CH2—O—)nNH or —COCH2(—OCH2—CH2)nNH—; and
‘n’ is an integer selected from 2 to 10, both inclusive;
R4 and R5 are independently NH2, or one or both of R4 or R5 are absent, with the proviso to the compound of Formula I, that in a compound of Formula I as above defined:
a) up to 5 but not more than 25% of the amino acids may be substituted with other natural or unnatural amino acids;
b) not more than 30% of the amino acids may be omitted;
c) in each said peptide sequence up to 2 amino acids may be added individually at any position;
d) up to 5 but not more than 25% of the peptide bonds may instead be replaced by reduced amide bond (—CH2NH—);
e) up to 100% of the amino acids may be D-amino acids;
f) up to 100% of the amino acids may be in reverse order.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein said mammalian PD1 ectodomain fragments are from human, murine, dog, horse or rat PD1.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein;
A is an amino acid sequence of from three amino acids to the full length of a peptide sequence of human or murine PD1 ectodomain fragments selected from FG loop, BC loop, C-C′ loop, C strand, C′ strand to C′-C″ loop as in table below, or is Glu-Asp;
hPD-1
mPD-1
BC Loop
SNTSESF
SNWSEDL
C Strand
VLNWYRM
MLNWNRL
C-C′ loop
SPSNQ
SPSNQ
C′ strand to C′-C″ loop
FPED
FCNG
FG loop
LAPKA
LHPKA
B is an amino acid sequence of from three amino acids to the full length of a peptide sequence of human or murine PD1 ectodomain fragments selected from BC loop, FG loop, C C′ loop to C′ strand, C strand, D strand, C′ strand to C′-C″ loop as in table below, or is Glu-Asp, or is absent;
hPD-1
mPD-1
BC Loop
SNTSESF
SNWSEDL
C Strand
VLNWYRM
MLNWNRL
C′ strand to C′-C″ loop
FPED
FCNG
C C′ loop to C′ strand
SPSNQTDKLAAFP
SPSNQTEKQAAFC
D Strand
FRVTQ
FQIIQ
FG loop
LAPKA
LHPKA
with the proviso that if A is the amino acid sequence SNTSESF and X is lysine then B cannot be the amino acid sequence SNTSESF;
Z is
(i) from one to four peptide sequences arranged in any order each being of from three amino acids up to the full length of a human or murine PD1 ectodomain fragment selected from BC loop, D strand, FG loop, G strand, C strand, F strand, C′ strand, C″ strand, C″-D loop, C′ strand to C′-C″ loop, C′ strand to C″ strand or D strand to DE loop;
(ii) G-L-Z′
G is an amino acid sequence of from three amino acids to the full length of a peptide sequence of human or murine PD1 ectodomain fragments from D-strand or is absent;
L is selected from —CO(CH2)n—NH—, or PEG 2-20 KD;
‘n’ is an integer selected from 2 to 10, both inclusive; and
Z′ is one to three peptide sequences arranged in any order each being of from three amino acids up to the full length of a human or murine PD1 ectodomain fragment selected from FG loop and G-strand; or
(iii) from one to four peptide sequences arranged in any order each being of from three amino acids up to the full length of a human or murine PD1 ectodomain fragment selected from D-strand, FG loop and G strand, wherein two or more amino acids of the peptide sequence combine together to form a lactam bond between any of the two fragments or within the fragment;
wherein said fragments are as defined in table below;
hPD-1
mPD-1
BC Loop
SNTSESF
SNWSEDL
C Strand
VLNWYRM
MLNWNRL
C′ Strand
TDKLAAFP
TEKQAAFC
C′ strand to C′-C″
FPED
FCNG
loop
C′ strand to C″
TDKLAAFPED
TEKQAAFCNG
strand
RSQP
LSQP
C″ Strand
RSQP
LSQP
C″-D loop
GQDCR
VQDAR
D Strand
FRVTQ
FQIIQ
F strand
GTYLCGAIS
GIYLCGAIS
FG loop
LAPKA
LHPKA
G Strand
QIKE
KIEE
D strand to DE loop
FRVTQLPNGR
FQIIQLPNRH
D is up to two peptide sequences arranged in any order each being of from three amino acids up to the full length of a human or murine PD1 ectodomain fragment selected from BC loop, FG loop, C C′ loop to C′ strand as in table below or is absent;
hPD-1
mPD-1
BC Loop
SNTSESF
SNWSEDL
C C′ loop to C′ strand
SPSNQTDKLAAFP
SPSNQTEKQAAFC
FG loop
LAPKA
LHPKA
E is up to four peptide sequences arranged in any order each being of from three amino acids up to the full length of a human or murine PD1 ectodomain fragment selected from BC loop, D strand, FG loop, C C′ loop to C′ strand, G strand, FG loop to G strand or is absent;
hPD-1
mPD-1
BC Loop
SNTSESF
SNWSEDL
C C′ loop to C′ strand
SPSNQTDKLAAFP
SPSNQTEKQAAFC
D Strand
FRVTQ
FQIIQ
FG loop
LAPKA
LHPKA
G Strand
QIKE
KIEE
FG loop to G strand
LAPKAQIKE
LHPKAKIEE
X and X′ are independently selected from lysine, ornithine, diaminopropionic acid, diaminobutyric acid or olefinic amino acid of formula
which is optionally linked with an additional lysine; or
X and X′ combine together forming a ring with olefinic amino acid which is optionally linked with an additional lysine; or
X′ is absent;
‘m’ is an integer selected from 1 to 6, both inclusive;
R1 is selected from group consisting of C2-C20 acyl, PEG 2-20 KD moiety; or absent,
R2 and R3 are independently selected from group consisting of C2-C20 acyl, PEG 2-20 KD, absent or Ra-L′;
Ra is selected from biotin or maleimido propionic acid;
L′ is selected from linkers —CO(CH2)n—NH—, —CO(CH2—CH2—O—)nNH or —COCH2(—OCH2—CH2)nNH—; and
‘n’ is an integer selected from 2 to 10, both inclusive;
R4 and R5 are independently NH2, or one or both of R4 or R5 are absent, with the proviso to the compound of Formula I, that in a compound of Formula I as above defined:
a) up to 5 but not more than 25% of the amino acids may be substituted with other natural or unnatural amino acids;
b) not more than 30% of the amino acids may be omitted;
c) in each said peptide sequence up to 2 amino acids may be added individually at any position;
d) up to 5 but not more than 25% of the peptide bonds may instead be replaced by reduced amide bond (—CH2NH—);
e) up to 100% of the amino acids may be D-amino acids;
f) up to 100% of the amino acids may be in reverse order.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein Z consists of one said peptide sequence and at least one of B, D or E is not absent.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein if B, D and E are absent then Z comprises from 2 to 4 said peptide sequences.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein Z is a combination of D strand, FG loop and G strand.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein X is lysine and X′ is absent.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein both X and X′ are lysine.

### Claim 9 (depends on 1)

The compound according to claim 1, wherein R2 and R3 are selected from C2-C20 acyl, or Ra-L′; wherein,
Ra is maleimido propionic acid;
L′ is —COCH2(—OCH2—CH2)nNH—; and
‘n’ is an integer selected from 2 to 10, both inclusive.

### Claim 10 (depends on 1)

The compound according to claim 1, wherein X′, D, E and R5 are absent and R4 is NH2.

### Claim 11

A compound selected from
Comp.
No.
Compound
Sequence ID
5
CGAISLAPKAQIKE-NH2
42
46
6
FRVTQK(SNTSESF)FRVTQAhxLAPKAQIKE-NH2
43
47
7
FRVTQK(SNTSESF)FRVTQLAPKAQIKE-NH2
44
48
11
SNTSESFK(SNQTDK)FRVTQLAPKAQIKE-NH2
45
52
12
SNTSESFK(SNQTDK)FRVTQK(LAP)AQIKE-NH2
46
53
22
47
63
23
64
24
65
27
SNTSESFKFRVTQLAPKAQIKE-NH2
68
28
SNTSESFKSNTSESFFRVTQLAPKAQIKE-NH2
69
37
SNTSESFK(LAP)FRVTQLAPKAQIKE-NH2
78
38
LAPK(LAP)FRVTQLAPKAQIKE-NH2
79
39
LAPKAQIKE-NH2
80
48
EKIQAKPALQTVRFK(FSESTNS)FSESTNS-NH2
89
49
ekiqakpalqtvrfk(fsestns)fsestns-NH2 Retro inverso (All D-amino acid)
90
69
SNWSEDLK(SNWSEDL)FQIIQLHPKAKIEE-NH2
110
70
EDK(ED)FRVTQLAPKAQIKE-NH2
111
71
SNTSESFK(ED)FRVTQLAPKAQIKE-NH2
112
72
LAPKAK(ED)FRVTQLAPKAQIKE-NH2
113
73
SNQTDKK(ED)FRVTQLAPKAQIKE-NH2
114
75
SNQTDKK(VLNWYRM)GIYLCGAISLAPKAQIKE-NH2
116
76
EDK(VLNWYRM)GIYLCGAISLAPKAQIKE-NH2
117
79
VLNWYRM(SNQTDK)GIYLCGAISLAPKAQIKE-NH2
120
82
SNWSEDLK(SNWSEDL)FQIIQLHPK(CH3(CH2)14CO)AKIEE-NH2
123
91
SNWSEDLK(SNWSEDL)FQIIQLHPK(MPA—NH—CH2—CH2—O—CH2—CH2—O—CO)AKIEE-NH2
132
99
SNTSESF-Orn-(SNTSESF)KAQIKE-NH2
140
100
SNTSESF-Dap-(SNTSESF)KAQIKE-NH2
141
101
SNTSESF-Dab-(SNTSESF)KAQIKE-NH2
142
107
LAPKA(SNQTDK)FRVTQLAPKAQIKE-NH2
148

### Claim 12 (depends on 3)

A compound according to claim 3 having formula (Ia)
or pharmaceutically acceptable salt thereof;
wherein;
A is an amino acid sequence of from three amino acids to the full length of a peptide sequence of human or murine PD1 ectodomain fragments selected from FG loop, BC loop, C′ strand, C-C′ loop, C strand, C′ strand to C′-C″ loop;
B is an amino acid sequence of from three amino acids to the full length of a peptide sequence of human or murine PD1 ectodomain fragments selected from BC loop, FG loop, C-C′ loop to C′ strand, C strand, D strand, C′ strand to C′-C″ loop or is absent;
with the proviso that if A is the amino acid sequence SNTSESF and X is lysine then B cannot be the amino acid sequence SNTSESF;
Z is from one to three peptide sequences arranged in any order each being of from three amino acids up to the full length of a peptide sequence of human or murine PD1 ectodomain fragments selected from D strand, FG loop, G strand, C strand and F strand; and
X is lysine.

### Claim 13 (depends on 12)

The compound according to claim 12, wherein A and B are independently an amino acid sequence of from three amino acids to the full length of said BC loop, with the proviso that if A is the amino acid sequence SNTSESF and X is lysine then B cannot be the amino acid sequence SNTSESF.

### Claim 14 (depends on 12)

The compound according to claim 12, wherein Z is D strand-FG loop-G strand.

### Claim 15 (depends on 12)

The compound according to claim 12, wherein R1, R2 and R3 are absent.

### Claim 16 (depends on 12)

The compound according to claim 12, wherein R3 is C16-acyl.

### Claim 17 (depends on 12)

The compound according to claim 12, wherein up to three amino acids are D-amino acids.

### Claim 18 (depends on 12)

The compound according to claim 12, wherein all amino acids are D-amino acids.

### Claim 19 (depends on 12)

The compound according to claim 12, comprising up to three reduced amide bonds (—CH2NH—).

### Claim 20 (depends on 1)

A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in claim 1, and a pharmaceutically acceptable diluent or carrier.

### Claim 21 (depends on 1)

A method of modulating an immune response mediated by PD-1 signaling pathway in a subject, comprising administering to the subject therapeutically effective amount of compound according to claim 1 such that the immune response in the subject is modulated.

### Claim 22 (depends on 1)

A method of inhibiting growth of tumor cells and/or metastasis in a subject, comprising administering to the subject a therapeutically effective amount of compound according to claim 1 capable of inhibiting the programmed cell death 1 (PD1) signaling pathway.

### Claim 23 (depends on 22)

The method of claim 22, wherein the tumor cells are of a cancer selected from the group consisting of melanoma, renal cancer, prostate cancer, breast cancer, colon cancer, and lung cancer.

### Claim 24 (depends on 23)

The method of claim 23, wherein the tumor cells are of a cancer selected from bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, and combinations of said cancers.

### Claim 25 (depends on 1)

A method of treating an infectious disease in a subject comprising administering to the subject a therapeutically effective amount of compound according to claim 1 to inhibit the programmed cell death 1 (PD1) signaling pathway such that the subject is treated for the infectious disease.

### Claim 26 (depends on 1)

A method of treating bacterial and viral infections in a subject comprising administering to the subject a therapeutically effective amount of compound according to claim 1 to inhibit the programmed cell death 1 (PD1) signaling pathway such that the subject is treated for the bacterial and viral infections.
